MDP Medexus Pharmaceuticals Inc.
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary products include IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis, psoriasis, and juvenile idiopathic arthritis; Rupall, a prescription allergy medication; and GRAFAPEX, an injection to treat allogeneic hematopoietic stem cell transplantation in adult and pediatric patients, acute myeloid leukemia (AML), and myelodysplastic syndrome. The company's products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, a ciprofloxacin and flucinolone acetonide; and intraarticular, a triamcinolone hexacetonide injectable suspension. In addition, it offers over the counter products comprising Nyda, a topical treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. was founded in 2000 and is based in Toronto, Canada.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Medexus Pharmaceuticals (TSE: MDP)
›
Medexus Pharmaceuticals (TSE: MDP) is listed on the Toronto Stock Exchange, where its shares trade in CAD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 90 employees.
The shares were at 5.710 CAD on 19 November 2026, up 111.5% over 52 weeks. Its 52-week range is 2.510 CAD to 6.050 CAD: the price is 5.6% below the high and 127.5% above the low.
Its market capitalisation is 179.44M CAD.
Medexus Pharmaceuticals reports return on equity of -4.9%, an operating margin of 7.3% and revenue up 17.6% year over year.
Its debt exceeds its cash by 17.87M USD, a debt-to-equity ratio of 0.45. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 5 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 7.640 CAD is 33.8% above the current price. The next earnings report is expected on 10 February 2027.